The Leukemia & Lymphoma Society and Epizyme Announce Achievement of Pre-clinical Milestone in DOT1L Personalized Therapeutic Partnership
3/13/2012 7:26:38 AM
WHITE PLAINS, N.Y. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Leukemia & Lymphoma Society (LLS) and Epizyme announced today that they have achieved a pre-clinical milestone in their partnership to develop Epizyme’s DOT1L-targeted histone methyltransferase inhibitor (HMTi) for Mixed Lineage Leukemia (MLL), a devastating acute leukemia that affects both pediatric and adult patients. Including this milestone, Epizyme has received, to date, $2.6 million of a potential $7.5 million in funding under the partnership with LLS to support the DOT1L program through Phase 1. Epizyme is creating personalized therapeutics for patients with genetically-defined cancers, with a focus on small molecule inhibitors of histone methyltransferases, an important epigenetic target class.